BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 237.08% | -33.22% | 32.11% | 11,461.88% | -6.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 237.08% | -33.22% | 32.11% | 11,461.88% | -6.68% |
| Cost of Revenue | 248.49% | 0.00% | -0.17% | -8.14% | -7.57% |
| Gross Profit | 231.12% | -38.91% | 50.67% | 17,816.77% | -6.21% |
| SG&A Expenses | 99.19% | 92.36% | 64.78% | 111.54% | 49.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.36% | 17.55% | 21.22% | 66.41% | 44.56% |
| Operating Income | -25.29% | -18.87% | -21.10% | 103.05% | -45.35% |
| Income Before Tax | -56.31% | 8.49% | 52.99% | 74.67% | -21.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.98% | 8.49% | 52.99% | 74.67% | -21.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 7.29% | -11.05% | -25.53% | -63.35% | -26.82% |
| Net Income | -57.63% | 8.45% | 53.48% | 74.87% | -22.21% |
| EBIT | -25.29% | -18.87% | -21.10% | 103.05% | -45.35% |
| EBITDA | -25.64% | -19.14% | -21.39% | 104.41% | -46.04% |
| EPS Basic | -45.16% | 20.69% | 60.19% | 78.53% | -4.61% |
| Normalized Basic EPS | -26.71% | -6.12% | -8.62% | 91.89% | -20.72% |
| EPS Diluted | -45.16% | 20.69% | 60.19% | 78.53% | -4.61% |
| Normalized Diluted EPS | -26.71% | -6.12% | -8.62% | 91.89% | -20.72% |
| Average Basic Shares Outstanding | 8.58% | 15.43% | 16.85% | 17.07% | 16.82% |
| Average Diluted Shares Outstanding | 8.58% | 15.43% | 16.85% | 17.07% | 16.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
